Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy

Haruyuki Kawai, Katsuyuki Kiura, Masahiro Tabata, Tadashi Yoshino, Ichiro Takata, Akio Hiraki, Kenichi Chikamori, Hiroshi Ueoka, Mitsune Tanimoto, Mine Harada

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We established several in vitro drug-resistant cell lines after continuous, long-term exposure of each drug to elucidate mechanisms of drug resistance. Whether drug resistance in these in vitro resistant cell lines reflects clinical drug resistance still remains unanswered. In this study, a pair of lung cancer cell lines was established from one patient with squamous cell carcinoma of the lung, with one line being established before and one line after combination chemotherapy (cisplatin/ifosfamide/vindesine). Combination chemotherapy selected resistant EBC-2/R cells, which showed cross-resistance to 4-hydroxyifosfamide (3.2-fold), cisplatin (2.3-fold), and methotrexate (3.7-fold) and collateral sensitivity to vindesine (0.77-fold) compared with parent EBC-2 cells. EBC-2/R cells showed decrease in intracellular accumulation of cisplatin, increase in intracellular concentration of glutathione (GSH), and overexpression of multidrug resistance-associated protein (MRP) 3 when compared with EBC-2 cells. A single cycle of chemotherapy was not sufficient to select other mechanisms of drug resistance, such as multidrug resistance-1/P-glycoprotein, MRPs 1, 2, 4, and 5, lung resistance-related protein, metallothionein IIa, glutathione S-transferase π, γ-glutamylcysteine synthetase (light and heavy chain), and excision repair cross complementing 1. Sequentially we established two cell lines, which cell lines showed the differences of the cisplatin resistance, expression level of MRP3, intracellular GSH level and intracellular accumulation of cisplatin. A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells.

Original languageEnglish
Pages (from-to)305-314
Number of pages10
JournalLung Cancer
Volume35
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Drug Resistance
Drug Therapy
Cell Line
Vindesine
Combination Drug Therapy
Lung Neoplasms
Glutamate-Cysteine Ligase
Ifosfamide
Metallothionein
Multiple Drug Resistance
Glutathione Transferase
Methotrexate
DNA Repair
Pharmaceutical Preparations
Glutathione
Squamous Cell Carcinoma
Light
Lung

Keywords

  • Accumulation
  • Cisplatin
  • Glutathione
  • In vivo
  • Methotrexate
  • MRP3
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. / Kawai, Haruyuki; Kiura, Katsuyuki; Tabata, Masahiro; Yoshino, Tadashi; Takata, Ichiro; Hiraki, Akio; Chikamori, Kenichi; Ueoka, Hiroshi; Tanimoto, Mitsune; Harada, Mine.

In: Lung Cancer, Vol. 35, No. 3, 2002, p. 305-314.

Research output: Contribution to journalArticle

Kawai, Haruyuki ; Kiura, Katsuyuki ; Tabata, Masahiro ; Yoshino, Tadashi ; Takata, Ichiro ; Hiraki, Akio ; Chikamori, Kenichi ; Ueoka, Hiroshi ; Tanimoto, Mitsune ; Harada, Mine. / Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. In: Lung Cancer. 2002 ; Vol. 35, No. 3. pp. 305-314.
@article{d2ebb5b468a24938b410a9c1070aae2e,
title = "Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy",
abstract = "We established several in vitro drug-resistant cell lines after continuous, long-term exposure of each drug to elucidate mechanisms of drug resistance. Whether drug resistance in these in vitro resistant cell lines reflects clinical drug resistance still remains unanswered. In this study, a pair of lung cancer cell lines was established from one patient with squamous cell carcinoma of the lung, with one line being established before and one line after combination chemotherapy (cisplatin/ifosfamide/vindesine). Combination chemotherapy selected resistant EBC-2/R cells, which showed cross-resistance to 4-hydroxyifosfamide (3.2-fold), cisplatin (2.3-fold), and methotrexate (3.7-fold) and collateral sensitivity to vindesine (0.77-fold) compared with parent EBC-2 cells. EBC-2/R cells showed decrease in intracellular accumulation of cisplatin, increase in intracellular concentration of glutathione (GSH), and overexpression of multidrug resistance-associated protein (MRP) 3 when compared with EBC-2 cells. A single cycle of chemotherapy was not sufficient to select other mechanisms of drug resistance, such as multidrug resistance-1/P-glycoprotein, MRPs 1, 2, 4, and 5, lung resistance-related protein, metallothionein IIa, glutathione S-transferase π, γ-glutamylcysteine synthetase (light and heavy chain), and excision repair cross complementing 1. Sequentially we established two cell lines, which cell lines showed the differences of the cisplatin resistance, expression level of MRP3, intracellular GSH level and intracellular accumulation of cisplatin. A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells.",
keywords = "Accumulation, Cisplatin, Glutathione, In vivo, Methotrexate, MRP3, Non-small-cell lung cancer",
author = "Haruyuki Kawai and Katsuyuki Kiura and Masahiro Tabata and Tadashi Yoshino and Ichiro Takata and Akio Hiraki and Kenichi Chikamori and Hiroshi Ueoka and Mitsune Tanimoto and Mine Harada",
year = "2002",
doi = "10.1016/S0169-5002(01)00430-5",
language = "English",
volume = "35",
pages = "305--314",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy

AU - Kawai, Haruyuki

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Yoshino, Tadashi

AU - Takata, Ichiro

AU - Hiraki, Akio

AU - Chikamori, Kenichi

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

AU - Harada, Mine

PY - 2002

Y1 - 2002

N2 - We established several in vitro drug-resistant cell lines after continuous, long-term exposure of each drug to elucidate mechanisms of drug resistance. Whether drug resistance in these in vitro resistant cell lines reflects clinical drug resistance still remains unanswered. In this study, a pair of lung cancer cell lines was established from one patient with squamous cell carcinoma of the lung, with one line being established before and one line after combination chemotherapy (cisplatin/ifosfamide/vindesine). Combination chemotherapy selected resistant EBC-2/R cells, which showed cross-resistance to 4-hydroxyifosfamide (3.2-fold), cisplatin (2.3-fold), and methotrexate (3.7-fold) and collateral sensitivity to vindesine (0.77-fold) compared with parent EBC-2 cells. EBC-2/R cells showed decrease in intracellular accumulation of cisplatin, increase in intracellular concentration of glutathione (GSH), and overexpression of multidrug resistance-associated protein (MRP) 3 when compared with EBC-2 cells. A single cycle of chemotherapy was not sufficient to select other mechanisms of drug resistance, such as multidrug resistance-1/P-glycoprotein, MRPs 1, 2, 4, and 5, lung resistance-related protein, metallothionein IIa, glutathione S-transferase π, γ-glutamylcysteine synthetase (light and heavy chain), and excision repair cross complementing 1. Sequentially we established two cell lines, which cell lines showed the differences of the cisplatin resistance, expression level of MRP3, intracellular GSH level and intracellular accumulation of cisplatin. A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells.

AB - We established several in vitro drug-resistant cell lines after continuous, long-term exposure of each drug to elucidate mechanisms of drug resistance. Whether drug resistance in these in vitro resistant cell lines reflects clinical drug resistance still remains unanswered. In this study, a pair of lung cancer cell lines was established from one patient with squamous cell carcinoma of the lung, with one line being established before and one line after combination chemotherapy (cisplatin/ifosfamide/vindesine). Combination chemotherapy selected resistant EBC-2/R cells, which showed cross-resistance to 4-hydroxyifosfamide (3.2-fold), cisplatin (2.3-fold), and methotrexate (3.7-fold) and collateral sensitivity to vindesine (0.77-fold) compared with parent EBC-2 cells. EBC-2/R cells showed decrease in intracellular accumulation of cisplatin, increase in intracellular concentration of glutathione (GSH), and overexpression of multidrug resistance-associated protein (MRP) 3 when compared with EBC-2 cells. A single cycle of chemotherapy was not sufficient to select other mechanisms of drug resistance, such as multidrug resistance-1/P-glycoprotein, MRPs 1, 2, 4, and 5, lung resistance-related protein, metallothionein IIa, glutathione S-transferase π, γ-glutamylcysteine synthetase (light and heavy chain), and excision repair cross complementing 1. Sequentially we established two cell lines, which cell lines showed the differences of the cisplatin resistance, expression level of MRP3, intracellular GSH level and intracellular accumulation of cisplatin. A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells.

KW - Accumulation

KW - Cisplatin

KW - Glutathione

KW - In vivo

KW - Methotrexate

KW - MRP3

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0036175650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036175650&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(01)00430-5

DO - 10.1016/S0169-5002(01)00430-5

M3 - Article

C2 - 11844606

AN - SCOPUS:0036175650

VL - 35

SP - 305

EP - 314

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -